PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.
Preliminary Select Third Quarter 2024 Results
Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.
Preliminary revenue by source for the third quarter is expected to be as follows:
Instruments revenue of approximately $19.1 million, representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue.
Consumables revenue of approximately $126.2 million, representing 10% growth over the corresponding prior year period. Consumables revenue consists of approximately $96.5 million of Chromium consumables revenue and $29.7 million of Spatial consumables revenue.
Services revenue of approximately $6.4 million, representing 48% growth over the corresponding prior year period.
Preliminary revenue by geography for the third quarter is expected to be as follows:
Americas revenue of approximately $87.8 million, an 11% decrease from the prior year period.
EMEA revenue of approximately $37.9 million, an 18% increase over the prior year period.
APAC revenue of approximately $26.0 million, a 15% increase over the prior year period.
Cash and cash equivalents of approximately $398 million as of September 30, 2024.
"Third quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes ...
